On the other hand, blocking IL-1β by anakinra in patients with the autoinflammatory syndrome neonatal-onset multisystem inflammatory disease (NOMID), a disease caused by autosomal dominant mutations in CIAS1 or NLRP3 [111], reduces systemic and organ-specific inflammation but not the bone manifestations. Here, NLRP3 is linked to autoinflammatory syndrome.